EUVIMEDEUVIMED entdecken
Multizentrische Studie

RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs

Xinjun Tang, Jie Hu, Renhua Guo, Yina Wang, Yu Yao, Liang Zeng, Haitao Wang, Haibo Shen, Jun Chen, Weina Huang, Lihua Liu, Ming Su und 15 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217455 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Letters, 2025. Verfasst von Xinjun Tang und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pralsetinib demonstrated impressive improvement of survival in non-small cell lung cancer (NSCLC) patients harbored de novo RET fusion. However, the efficacy in patients with acquired RET fusion after resistance to EGFR/ALK-TKIs has only been reported on a case-by-case basis, and the strategy for overcoming the acquired RET fusion has not been fully investigated. This multicenter, real-world analysis enrolled 32 patients with unresectable NSCLC harbored acquired RET fusion after resistance to EGFR/ALK-TKIs in 23 centers across China from July 1st, 2018 to Nov 23rd, 2022. Epidemiological, clinical, genetic, and treatment data were collected. The primary outcome was time to treatment failure (TTF). Secondary outcomes were overall survival (OS), objective response rate (ORR), disease control rate (DCR) and toxicity. In real-world context, patients underwent pralsetinib-based treatment had a higher proportion of central nervous system metastasis. EGFR 19del was the predominant mutation type (62.5 %) prior to acquired RET fusion. CCDC6 was the commonest RET fusion partner (40.6 %). "Clonal RET fusion" (c-RET) and "subclonal RET fusion" (s-RET) were defined according to the RET fusion allele frequency. Patients with c-RET had higher proportions of undetected EGFR mutation and KIF5B-RET fusion. First-line pralsetinib-based therapy had notably superior median TTF when compared to their counterparts (8.03 versus 4.30 months, P = 0.016). Notably, patients with c-RET had a better prognosis than those with s-RET (median TTF: NR versus 5.67 months, P = 0.037, median OS: NR versus 9.83 months, P = 0.047). In conclusion, pralsetinib-based therapy may be a potential strategy to overcome acquired RET fusion after resistance to EGFR/ALK-TKIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsOncogene Proteins, FusionProtein Kinase InhibitorsProto-Oncogene Proteins c-retAdultAgedFemaleHumansMaleMiddle AgedAnaplastic Lymphoma KinaseChinaErbB ReceptorsMutationPyrazolesPyrimidinesPyridines

Stichwörter der Autor:innen

Acquired RET fusionAllele frequencyEfficacyPralsetinibResistance mechanisms

Substanzen

ALK protein, humanAnaplastic Lymphoma KinaseEGFR protein, humanErbB ReceptorsOncogene Proteins, FusionpralsetinibProtein Kinase InhibitorsProto-Oncogene Proteins c-retPyrazolesPyrimidines

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai Geriatrics Medical Center, Shanghai, China. Electro…
  • Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Department of Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Department of Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

Zitieren

APA

Tang, X., Hu, J., Guo, R., Wang, Y., Yao, Y., Zeng, L., Wang, H., Shen, H., Chen, J., Huang, W., Liu, L., Su, M., Yu, Z., Mao, W., Wang, J., Tao, H., Dong, G., Cai, C., Xie, Y., …, & Liang, F. (2025). RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217455

Vancouver

Tang X, Hu J, Guo R, Wang Y, Yao Y, Zeng L, et al. RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217455

BibTeX
@article{Tang2025,
  author = {Tang, Xinjun and Hu, Jie and Guo, Renhua and Wang, Yina and Yao, Yu and Zeng, Liang and Wang, Haitao and Shen, Haibo and Chen, Jun and Huang, Weina and Liu, Lihua and Su, Ming and Yu, Zhuang and Mao, Weidong and Wang, Jinliang and Tao, Haitao and Dong, Guilan and Cai, Chang and Xie, Yupeng and Qu, Tao and Zhang, Yan and Shen, Wei and Cao, Jing and Cai, Xin and Kong, Wencui and Li, Xiaoxue and Liang, Fei},
  title = {RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217455}
}
Kostenlos starten →